1. Home
  2. ADAM vs DBVT Comparison

ADAM vs DBVT Comparison

Compare ADAM & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ADAM

Adamas Trust Inc.

HOLD

Current Price

$10.14

Market Cap

826.7M

Sector

Technology

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$14.09

Market Cap

948.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADAM
DBVT
Founded
2003
2002
Country
United States
France
Employees
N/A
90
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
826.7M
948.8M
IPO Year
2003
2014

Fundamental Metrics

Financial Performance
Metric
ADAM
DBVT
Price
$10.14
$14.09
Analyst Decision
Strong Buy
Buy
Analyst Count
3
7
Target Price
$9.17
$32.04
AVG Volume (30 Days)
885.3K
382.0K
Earning Date
04-29-2026
05-12-2026
Dividend Yield
11.87%
N/A
EPS Growth
196.49
10.26
EPS
0.87
N/A
Revenue
N/A
$5,636,000.00
Revenue This Year
N/A
$35.04
Revenue Next Year
$5.08
$2,360.78
P/E Ratio
$11.68
N/A
Revenue Growth
N/A
35.77
52 Week Low
$6.45
$8.80
52 Week High
$10.36
$26.19

Technical Indicators

Market Signals
Indicator
ADAM
DBVT
Relative Strength Index (RSI) 72.70 45.30
Support Level $8.61 $12.75
Resistance Level N/A $14.68
Average True Range (ATR) 0.27 0.71
MACD 0.13 0.15
Stochastic Oscillator 88.84 65.07

Price Performance

Historical Comparison
ADAM
DBVT

About ADAM Adamas Trust Inc.

Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing, and managing mainly mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit-sensitive single-family and multi-family assets.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: